Accession Number:



AAV9 Gene Therapy Using a Novel Engineered MIS to Treat Ovarian Cancer

Descriptive Note:

Technical Report,15 Jun 2018,14 Jun 2019

Corporate Author:

Massachusetts General Hospital Boston United States

Personal Author(s):

Report Date:


Pagination or Media Count:



There is a compelling unmet need for any ovarian cancer therapy effective against chemoresistant recurrences, and gene therapy approaches in cancer have been largely underutilized. Furthermore, gene therapy allows delivery of Mullerian Inhibiting Substance MIS at concentrations hitherto unachievable in in vivo models. Thus, AAV9-delivered MIS permits testing in vivo, for the first time, the hypothesis that a fetal inhibitor can be developed as an effective anti-cancer agent, initially against patient-derived xenografts PDXs in immunosuppressed mice. We hypothesized that MIS will be an effective and safe therapy for women with recurrent ovarian cancer, which is usually refractory to chemotherapy and most often a death sentence. Our preliminary results indicate that MIS is a potent inhibitor of ovarian cancer in vitro and in vivo however, only a subset of tumors respond to MIS therapy, and both the mechanism of inhibition and the determinants of response remain poorly understood. The purpose of the project is to test the response to MIS using patient-derived primary ovarian cancer cells, elucidate the mechanism of action using next generation sequencing technologies, identify biomarkers of response, and test the efficacy of MIS gene therapy approach in clinically relevant ovarian cancer models.

Subject Categories:

  • Medicine and Medical Research

Distribution Statement: